Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia

References

• Cheson BD, Pfistner B, Juweid ME, et al Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Kühnemund A, Liebisch P, Bauchmüller K, et al ‘Light-chain escape-multiple myeloma’ – an escape phenomenon from plateau phase: report of the largest patient series using LC monitoring. J Cancer Res Clin Oncol 2009;135:477–484.
   PubMed Web of Science ®Google Scholar
• Leleu X, Soumerai J, Roccaro A, et al Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009;27:250–255.
   PubMed Web of Science ®Google Scholar
• Kimby E, Treon SP, Anagnostopoulos A, et al Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006;6:380–383.
   PubMedGoogle Scholar
• Rourke M, Anderson KC, Ghobrial IM. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma 2010;51:1779–1792.
   PubMed Web of Science ®Google Scholar
• Gill S, Carney D, Ritchie D, et al The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol 2010;21:331–334.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al Guidelines for the diagnosis and treatment of chronic lymphocytic leukaemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Stroobants S, Hoekstra OS, et al Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571–578.
   PubMed Web of Science ®Google Scholar
• Bartel TB, Haessler J, Brown TL, et al F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009;114:2068–2076.
   PubMed Web of Science ®Google Scholar
• Morel P, Duhamel A, Gobbi P, et al International prognostic scoring system for Waldenstrom's macroglobulinemia. Blood 2009;113:4163–4170.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Ioakimidis L, et al Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 2009;113:3673–3678.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Jacobson JL, Gertz MA, et al Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SWOG S9003). Semin Oncol 2003;30:220–225.
   PubMed Web of Science ®Google Scholar
• Treon S, Hunter Z, Matous J, et al Phase II study of bortezomib in Waldenstrom's macroglobulinemia: results of WMCTG Trial 03‐248. Blood 2005;106(Suppl. 1): Abstract 11.
   PubMed Web of Science ®Google Scholar
• Chen CI, Kouroukis CT, White D, et al Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570–1575.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Abonour R, Heffner LT, et al Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol 2009;147:677–680.
   PubMed Web of Science ®Google Scholar
• Leblond V, Lévy V, Maloisel F, et al Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood 2001;98:2640–2644.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis M-C, et al Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25:3344–3349.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zervas C, Zomas A, et al Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia. Clin Lymphoma 2002;3:163–166.
   PubMedGoogle Scholar
• Gertz MA, Rue M, Blood E, et al Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047–2055.
   PubMed Web of Science ®Google Scholar
• Foran JM, Rohatiner AZ, Coiffier B, et al Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle cell lymphoma. J Clin Oncol 1999;17:546–553.
   PubMed Web of Science ®Google Scholar
• Thalhammer-Scherrer R, Geissler K, Schwarzinger I, et al Fludarabine therapy in Waldenström's macroglobulinemia. Ann Hematol 2000;79:556–559.
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, et al The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009;23:153–161.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Fonseca R, Greipp PR, et al Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004;101:2593–2598.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Gertz MA, Kastritis E, et al Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009;27:120–126.
   PubMed Web of Science ®Google Scholar
• Johnson SA, Owen RG, Oscier DG, et al Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders. Clin Lymphoma 2005;5:294–297.
   PubMedGoogle Scholar